Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Shares Outstanding (Weighted Average) (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $69.7 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 0.7% year-over-year to $69.7 million; the TTM value through Mar 2026 reached $69.7 million, up 0.7%, while the annual FY2025 figure was $69.3 million, 19.02% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $69.7 million in Q1 2026 for Bicycle Therapeutics, up from $69.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $69.7 million in Q1 2026 and bottomed at $29.6 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $47.2 million, with a median of $42.6 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) surged 72.21% in 2024 and then increased 0.7% in 2026.
  • Bicycle Therapeutics' Shares Outstanding (Weighted Average) stood at $29.7 million in 2022, then grew by 20.0% to $35.6 million in 2023, then soared by 63.54% to $58.2 million in 2024, then grew by 19.02% to $69.3 million in 2025, then grew by 0.58% to $69.7 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $69.7 million, $69.3 million, and $69.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.